X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AJANTA PHARMA Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA Quarterly Results   (AJPH)

Here are the latest quarterly results of AJANTA PHARMA. For more details, see the AJANTA PHARMA financial fact sheet and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

AJANTA PHARMA Quarterly Results

No. of Mths
Qtr. Ending
3
Jun-17
*
3
Sep-17
*
3
Dec-17
*
3
Mar-18
*
3
Jun-18
*
3
Sep-18
*
3
Dec-18
*
3
Mar-19
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m4,7315,4045,8715,3035,1105,4414,8515,152 
Other income Rs m489215252811524416 
Turnover Rs m4,7795,4966,0225,3565,1915,5944,8955,168 
Expenses Rs m3,4573,5673,8963,9083,5353,7793,7783,881 
Gross profit Rs m1,2751,8371,9751,3951,5751,6621,0731,271 
Depreciation Rs m134146150166172175187188 
Interest Rs m11112118 
Profit before tax Rs m1,1871,7831,9751,2801,4831,6389301,092 
Tax Rs m239464501335425385261203 
Profit after tax Rs m9481,3191,4759451,0581,254669889 
Gross profit margin %26.934.033.626.330.830.522.124.7 
Effective tax rate %20.226.025.326.228.723.528.018.6 
Net profit margin %20.024.425.117.820.723.013.817.3 
Diluted EPS Rs 10.8 15.0 16.8 10.7 12.0 14.3 7.6 10.1  
Diluted EPS (TTM) Rs 54.8 55.0 55.5 53.3 54.5 53.8 44.6 44.0  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: AJANTA PHARMA 4QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   J.B.CHEMICALS  INDOCO REMEDIES  CIPLA  ORCHID PHARMA LTD  GSK PHARMA  

Compare AJANTA PHARMA With:   J.B.CHEMICALS  INDOCO REMEDIES  CIPLA  ORCHID PHARMA LTD  GSK PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Yes Bank & Sun Pharma Top Gainers(12:30 pm)

Share markets in India recovered early losses and are presently trading on a positive note. Barring IT sector and FMCG sector, all sectoral indices are trading.

Views on news

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 20, 2019 03:21 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AJANTA PHARMA

AJANTA PHARMA - ADCOCK INGRAM COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS